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ABSTRACT 
Objective: To develop a UV-derivative spectrophotometric method with zero-crossing determinations for the simultaneous quantification of 
ibuprofen (IBU) and caffeine (CAF) in fixed-dose combination formulations (soft gelatin capsules). The proposed method was validated, and it was 
applied to determine the in vitro dissolution performance of IBU and CAF from a commercial formulation. 
Methods: The method is based on the use of the second-derivatives of the zero-order spectra and measurement at zero-crossing wavelengths. 
Linearity, accuracy, precision, stability, and influence of the filter were evaluated. Dissolution profiles of IBU and CAF were obtained with the USP 
Apparatus 2 at 100 rpm and 900 ml of 0.1 M phosphate buffer pH 7.4 as dissolution medium. Dissolution samples were treated with the proposed 
UV-derivative method and results were compared with data previously published. 
Results: The zero-crossing points for the determination of IBU and CAF were found at 235.6 nm and 218.8 nm, respectively. The method was linear 
in the range of 7.5-15 µg/ml for IBU and 5-25 µg/ml for CAF (R2>0.999, *P<0.05). The precision and accuracy of the method were within acceptable 
criteria (CV<0.99% and recovery 97.97% for IBU and CV<1.76% and recovery 99.05% for CAF). Fiberglass filters were the best option to filter 
samples and stability of all drugs was adequate when solutions were stored at 25 °C during 24 h. Dissolution of IBU and CAF at 60 min was 99-100% 
with dissolution profiles of sigmoidal S-shape. Weibull function and Logistic were the best-fit models that describe the in vitro dissolution 
performance of both drugs. 
Conclusion: The proposed UV-derivative method allows the simultaneous determination of IBU and CAF in fixed-dose combination formulations. 
The method generates reliable information that can be compared with published data. The proposed UV-derivative method is rapid and simple and 
can be easily adopted for routine analysis of IBU and CAF. 
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Many drug products containing mixtures of drugs are manufactured 
as fixed-dose combination formulations. Some advantages have been 
identified for this kind of formulations: 1. Greater efficacy compared 
with higher dose monotherapy; 2. Reduced risk of adverse reactions 
relative to higher dose monotherapy; 3. Lower overall costs, and 4. 
Improve medication concordance [1]. These advantages can be seen 
when treating different conditions with various combinations of 
drugs. Fixed-dose combination formulations of ibuprofen (IBU) and 
caffeine (CAF) are widely available as over-the-counter products. 
IBU is a non-steroidal anti-inflammatory drug (NSAID) with 
analgesic, anti-inflammatory, and antipyretic properties [2]. Some 
authors have studied the effect of CAF on pain management [3-5]. 
CAF is an extremely common drug in commercial products, and it 
occurs in a wide range of cold remedies, analgesics and other types 
of medicines. CAF is clinically safe, and it has good pH-independent 
aqueous solubility in the physiological pH range (~50 mg/ml) [6]. 
Chemical structures of IBU and CAF are shown in fig. 1. 
 
 
Fig. 1: Chemical structures of ibuprofen (left) and caffeine 
(right) 
 
A review of analgesic effect of IBU and CAF mixture was previously 
reported [7]. The use of this combination in preclinical studies [8, 9], 
the effectiveness of a single dose of IBU/CAF tablets in postoperative 
pain [10] and especially in molar surgeries has been widely 
documented [10-14]. 
According to Biopharmaceutics Classification System (BCS) criteria 
drugs with low solubility and high permeability are classified as 
class II drugs [15]. Several authors have classified IBU as a class II 
drug [16, 17]. By the available scientific information, formulations 
with IBU as the only active pharmaceutical ingredient (API), are 
candidates to waiver in vivo studies. A biowaiver monograph for 
immediate-release solid oral dosage forms containing IBU has been 
published [2]. However, only fixed-dose combinations containing 
BCS class I, or class III, or a combination of class I and class III may 
be candidates for a biowaiver [18] so this approach for IBU/CAF 
drug products, is not applicable. Official dissolution test for IBU 
suspensions and tablets are described in the United States 
Pharmacopeia (USP) [19]. Both methods use the USP Apparatus 2 at 
50 rpm and 900 ml of phosphate buffer pH 7.2 as dissolution 
medium. To date, no official dissolution test for IBU/CAF fixed-dose 
combination formulations is available [19]. 
Several authors have studied the simultaneous determination of CAF 
combined with some NSAIDs in pharmaceutical formulations [20, 21]. 
The quantification of the ternary mixture of acetaminophen (ACE), 
IBU, and CAF in solid dosage forms using analytical methods as UV and 
HPLC [22, 23] as well as voltammetric determination [24] have been 
previously described. Specifically, for IBU/CAF mixture, analytical 
methods with gas chromatography in pharmaceutical dosage forms 
[25], Raman spectroscopy in water samples [26] and fluorescence in 
urine samples [27] were recently reported. However, in a complete 
review of spectrophotometric methods for determination of some 
mixtures the combination of IBU and CAF is not included [28]. 
In the present study, a rapid and simple UV-derivative method with 
measurements at zero-crossing points is proposed for determination 
of IBU and CAF in fixed-dose combination formulations (soft gelatin 
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capsules). The method was applied in dissolution studies using USP 
Apparatus 2 (paddle) at 100 rpm and 0.1 M phosphate buffer pH 7.4 
as dissolution medium. The objective is to have a reliable and easy 
method to determine IBU and CAF using the minimum possible 
analytical resources. Results were compared with published data. 
IBU and CAF standards were purchased from Sigma-Aldrich Co. (St. 
Louis MO, USA). Sodium phosphate monobasic and dibasic crystals 
and methanol HPLC grade were purchased from J. T. Baker-Mexico 
(Xalostoc, Mexico). The fixed-dose combination formulation of IBU 
and CAF (200/65-mg, respectively) used was Advil Lift® capsules 
(Procaps S. A., Barranquilla Colombia). 
For UV derivative analysis, a double beam UV/Vis 
spectrophotometer (Perkin Elmer Lambda 35, Waltham MA, USA) 
with 1-cm quartz cells was used. The operating conditions were 
second-derivative (2D) mode with scan speed of 240 nm/min, slit 
width 2.0 nm and sampling interval 1.0 nm. 
The preparation of standard solutions of IBU and CAF were as follows: 
10 mg of each drug were separately added to 10 ml volumetric flasks. 
A volume of 5 ml of methanol was added to each one then, flasks were 
sonicated during 10 min. Later, both flasks were diluted to the mark 
with 0.1 M phosphate buffer pH 7.4. From both stock solutions, five 
solutions of IBU (7.5-15 µg/ml) and five solutions of CAF (5-25 µg/ml) 
in 0.1 M phosphate buffer pH 7.4 were prepared. Then, zero-order 
spectra of all solutions from 200 to 350 nm, using 1-cm quartz cells, 
were recorded and stored. To quantify IBU and CAF, the stored spectra 
of the standard calibration curves were used to calculate the 2D. To 
quantify IBU and CAF in dissolution samples, the zero-order spectra of 
filtered solutions at adequate concentrations were recorded and 
stored. Subsequently, the 2D spectra of IBU and CAF, as well as data of 
standard calibration curves, were used to calculate the percent 
dissolved of each drug at previously established sampling times. 
To test linearity, two standard calibration curves of IBU and CAF were 
plotted. Data were fitted by linear regression analysis and the 
correlation coefficients and regression analysis of variance (ANOVA) 
were calculated. The 95% Confidence Interval (CI95%) for the intercept 
of each mean standard calibration curve was calculated. Precision was 
demonstrated with the calculation of percent of coefficient of variation 
(%CV): [(standard deviation/mean) × 100] of response factor. 
Response factor represents the proportionality of response vs. drug 
concentration. A CV≤2% was considered as a good criterion. Accuracy 
and precision were evaluated with the preparation of three synthetic 
mixtures of IBU and CAF with concentrations within standard 
calibration curves range of each drug. Then, four samples of each 
solution and a standard calibration curve of each drug were analyzed 
with the proposed UV-derivative method. Accuracy was validated by 
recovery data and precision with the calculation of %CV. Added vs. 
recovered concentrations were plotted and linear regression analysis 
were calculated. The CI95% of slopes and intercepts, as well as %CV at 
each concentration level, were estimated. Drug retention by some 
kinds of filters was evaluated by response of IBU and CAF before and 
after a synthetic mixture of both drugs was filtered (10 µg/ml of IBU 
and 20 µg/ml of CAF). Nitrocellulose and fiberglass filters were tested. 
Percent of absolute difference (%AD): [((initial response–final 
response)/initial response) × 100] was calculated with 10 samples. 
The IBU and CAF stability was evaluated by stored a synthetic mixture 
(13 µg/ml of IBU and 20 µg/ml of CAF) at 4 and 25 °C during 24 and 
72 h. The %AD was calculated by triplicate at each temperature and 
sampling time. 
Dissolution profiles of IBU/CAF capsules were obtained with a USP 
Apparatus 2 (paddle) (Sotax AT-7 Smart, Switzerland) at 100 rpm 
and 900 ml of 0.1 M phosphate buffer pH 7.4 (37.0±0.5 °C). Each 
dissolution profile was calculated with 12 replicates. After addition 
of capsules, 5 ml of filtered dissolution sample was withdrawn at 10, 
25, 30, 45, and 60 min. All samples were diluted at adequate 
concentrations and they were analyzed by the proposed UV-
derivative method. Dissolved drug at 60 min (Q60) was used for 
comparative purposes. In order to describe the in vitro dissolution 
performance of IBU/CAF from commercial capsules mean 
dissolution time (MDT) and dissolution efficiency (DE) were 
calculated. Both model-independent parameters have been suggested 
as suitable parameters to compare dissolution profiles [29, 30] and to 
establish an in vitro/in vivo correlation [31]. Additionally, dissolution 
data of both drugs were fitted by several mathematical models 
commonly used in dissolution studies as Weibull, logistic, Gompertz 
and Probit. Equations are shown in table 1. Best-fit model was the one 
that presented highest R2adjusted and lowest Akaike Information 
Criterion (AIC) [32]. DDSolver add-in program was used to calculate 
MDT and DE and fit dissolution data [33]. 
 
Table 1: Mathematical models used to fit dissolution data of IBU 
and CAF 
Model Equation 
Weibull 
𝐹 = 𝐹𝑚𝑎𝑥 ∙ �1 − 𝑒
−𝑡
𝛽
𝛼 � 
Logistic 
𝐹 = 𝐹𝑚𝑎𝑥 ∙
𝑒𝛼+𝛽∙𝑙𝑜𝑔(𝑡)
1 + 𝑒𝛼+𝛽∙𝑙𝑜𝑔(𝑡)
 
Gompertz 𝐹 = 𝐹𝑚𝑎𝑥 ∙ 𝑒−𝛽∙𝑒
−𝑘∙𝑡 
Probit 𝐹 = 100 ∙ ɸ[𝛼 + 𝛽 ∙ 𝑙𝑜𝑔(𝑡)] 
IBU: ibuprofen. CAF: caffeine 
 
The zero-order spectra of 0.1 M phosphate buffer pH 7.4 solutions of IBU 
at 10 µg/ml, CAF at 15 µg/ml and a synthetic mixture of both drugs 
(MIX) at same concentrations are depicted in fig. 2A. The zero-order 
spectrum of MIX solution demonstrated a marked overlapping so that 
the direct and simultaneous determination of IBU and CAF was not 
possible. The 2D of zero-order spectra of five standard solutions of IBU 
(7.5-15 µg/ml) and five solutions of CAF (5-25 µg/ml), as well as MIX 
solution (10 µg/ml of IBU and 15 µg/ml of CAF), are shown in fig. 2B. The 
zero-crossing points for determination of IBU and CAF were identified at 
235.6 and 218.8 nm, respectively. At these wavelengths, all analytical 
signals were proportional to the concentrations of drugs and as can be 
seen, no interference of each drug was found. 
 
 
Fig. 2: (A) Zero-order spectra of a solution of ibuprofen (IBU) at 
10 µg/ml, caffeine (CAF) at 15 µg/ml and a synthetic mixture of 
both drugs (MIX) at same concentrations. (B) Second-derivative 
(2D) of standard calibration curves and MIX solution. Vertical 
lines show the zero-crossing points used to quantify IBU (235.6 
nm) and CAF (218.8 nm) 
 
Of each drug, two standard solutions were prepared, and mean linear 
regression equations were as follows: y=0.0502x‒0.0154 for IBU and 
y=0.0797x+0.0138 for CAF. All standard calibration curves were 
significant (R2>0.999, *P<0.05). Plots are shown in fig. 3A and fig. 3B. The 
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CI95% calculated for intercept was-0.044 to 0.013 for IBU and-0.014 to 
0.041 for CAF. The %CV of response factor was 1.75% for IBU and 1.86% 
for CAF. The linear regression equations calculated to test accuracy were 
as follows: y=1.0291x‒0.5758 for IBU and y=1.053x‒0.7383 for CAF. All 
linear regressions were significant (R2>0.99, *P<0.05). Plots are shown in 
fig. 3C and fig. 3D. The CI95% for slopes and intercepts, respectively, were 
as follows: 0.56 to 1.49 and ‒6.10 to 4.95 for IBU and 0.66 to 1.44 and 
‒5.91 to 4.43 for CAF. The %CV of recovery data were 0.58 to 0.99% for 
IBU and 0.34 to 1.76% for CAF. Results shown a good accuracy and 
precision of the proposed UV-derivative method. 
 
 
Fig. 3: (A) and (B) Standard calibration curves (mean values, n=2). (C) and (D) Synthetic mixtures (mean values, n=4) of ibuprofen (IBU) 
and caffeine (CAF). All linear regressions were significant (*P<0.05) 
 
The lowest values of %AD to test the influence of the filter were 
0.46% for IBU and 4.6% for CAF, both data were calculated with 
fiberglass filters so, this kind of filter was used in dissolution studies. 
Values of %AD to test the stability of IBU at 25 °C and 24 and 72 h 
were-3.25 and-4.74%, respectively. Data of CAF at same conditions 
were 0.40 and 0.88%. Values of %AD of IBU at 4 °C and at 24 and 72 
h were-5.03 and-7.05%, respectively. Data of CAF at same conditions 
were-0.6 and-0.63%. Results suggest better stability of a synthetic 
mixture of IBU and CAF at 25 °C for 24 h. 
Dissolution profiles of IBU and CAF from fixed-dose combination 
formulation are depicted in fig. 4. The Q60, MDT, and DE values are 
shown in table 2. 
The in vitro dissolution performance of IBU and CAF shown a 
sigmoidal S-shape with a complete drug release at 60 min (100%). 
Application of the UV-derivative method showed that excipients do 
not affect the accuracy of our results since recovery (expressed as 
Q60 data) is similar than results obtained with gas chromatography 
and HPLC methods applied at IBU/CAF fixed-dose combination 
formulations (99-100% for both drugs) [25]. 
The R2adjusted and AIC values as a result of adjusting IBU and CAF 
dissolution data by several mathematical models are shown in table 
3. Weibull function was the best-fit model for IBU data and the 
Logistic equation for CAF data. 
Weibull and Logistic models cannot describe drug release kinetics, but 
they can describe the curve in terms of applicable parameters [34]. 
The shape parameter β characterizes the dissolution profile as 
exponential (β=1); as sigmoid S-shaped, with upward curvature 
followed by a turning point (β>1); or as parabolic, with a steeper initial 
slope that is consistent with the exponential (β<1) [35]. In the present 
study, mean β values±standard deviation of IBU (Weibull) and CAF 
(Logistic) were 2.79±0.37 and 10.08±1.93, respectively, and since β 
values were>1 sigmoidal profile for both drugs was considered. 
Similar results have been reported by several authors wherein a 
dissolution study of IBU suspensions (USP Apparatus 2 and 4 and 
phosphate buffer pH 7.2) two formulations were well fitted by Weibull 
function (R2adjusted>0.99) [36]. Another dissolution study but with 
ACE/IBU fixed-dose combination formulations (USP Apparatus 2 and 4 
and 0.1 M phosphate buffer pH 7.4) reported a best-fit with Weibull 
distribution (R2adjusted>0.999) for both drugs [37]. The fit of dissolution 
data to the Weibull function and Logistic model emphasized the S-
shape or sigmoidal dissolution profiles [34]. 
 
 
Fig. 4: Dissolution profiles of ibuprofen (IBU) and caffeine (CAF) 
obtained with USP Apparatus 2 at 100 rpm and 900 ml of 0.1 M 
phosphate buffer pH 7.4 as dissolution medium. Mean 
value±standard deviation, n=12 
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Table 2: Model-independent parameters of IBU and CAF 
Drug Q60 (%) MDT (min) DE (%) 
IBU 99.05±0.58 22.81±0.52 61.39±0.89 
CAF 100.37±0.72 22.23±0.72 63.17±1.15 
Mean value±standard error medium, n=12. IBU: ibuprofen. CAF: caffeine. Q60: dissolved drug at 30 min. MDT: mean dissolution time. DE: dissolution 
efficiency 
 
Table 3: Criteria used to find the best-fit model of IBU and CAF dissolution data 
Drug Weibull Logistic Gompertz Probit 
R2adjusted 
IBU 0.9912 0.9819 0.9838 0.9826 
CAF 0.9937 0.9964 0.9963 0.9953 
AIC 
IBU 21.65 25.10 24.44 25.10 
CAF 20.11 14.88 13.33 16.56 
Mean value±standard error medium, n=12. IBU: ibuprofen. CAF: caffeine 
 
On the other hand, the in vitro dissolution performance of CAF from 
fixed-dose formulations has been previously reported. ACE/CAF 
tablets were tested with USP Apparatus 1 at 100 rpm and 900 ml of 
fat-rich media as dissolution medium. Under these conditions more 
than 80% of dissolved CAF at 20 min was found [6]. CAF in a ternary 
mixture of drugs (tablets) was dissolved with USP Apparatus 1 at 
100 rpm and 900 ml of 0.1 N HCl. More than 80% of dissolved CAF at 
20 min was found [38]. In our in vitro dissolution study, more than 
80% of dissolved CAF was found but at 30 min (82.99±9.63%, mean 
value±standard deviation). As the dissolution profile of CAF shown a 
sigmoidal S-shape it is not possible to find 80% of dissolved drug at 
20 min but 10 min latter this dissolution extent was achieved. 
Additionally, CAF as only API manufactured in three different 
hypromellose (HPMC)-based controlled release tablets were tested 
with USP Apparatus 3 (10 and 15 dpm), water and biorelevant 
media (fed and fasted) [39]. Dissolution data were well fitted by the 
Weibull function (R2>0.98) and under certain conditions shape 
parameter b was>1. In that study no other mathematical model to fit 
dissolution data was considered however and as previously stated, 
Weibull distribution emphasized the S-shape or sigmoidal 
dissolution profiles. 
The proposed UV-derivative method was an analytical procedure 
successfully used to simultaneously identify IBU and CAF in fixed-
dose combination formulations. This kind of methods avoid the use 
of toxic solvents such as those used by HPLC methods and expensive 
laboratory equipment requiring specialized maintenance. The 
proposed method is an analytical procedure that not needing any 
additional mathematical calculations and can be easily adopted for 
routine analysis of IBU/CAF soft gelatin capsules. 
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